ArticleAmerican journal of translational research2026
Beclin 1 level combined with Gensini score and low-density lipoprotein cholesterol correlate strongly with multi-vessel disease.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the correlation between serum Beclin 1 levels and multi-vessel disease (MVD).
methodsA total of 169 participants were enrolled in this retrospective study. Based on coronary angiographic findings, 106 patients diagnosed with coronary heart disease (CHD) were categorized into single-vessel disease (SVD) and MVD groups, and their Gensini scores were calculated respectively. General demographic data and serum biochemical indicators were collected. Serum Beclin 1 concentration was detected by enzyme-linked immunosorbent assay. The differential expression of Beclin 1 among the three groups was compared and analyzed. Logistic regression models and receiver operating characteristic (ROC) curves were used to explore the association between Beclin 1 level and MVD.
resultsCompared to the control group, Beclin 1 levels were significantly decreased in both the groups, with the lowest level observed in the MVD group [2.45 (1.69, 4.17), 2.64 (2.24, 2.89), 1.09 (0.66, 1.78), P<0.001]. Multivariate analysis results demonstrated that Gensini score was an independent risk factor for MVD (OR = 1.045, 95% CI: 1.018-1.090, P<0.001), while Beclin 1 (OR = 0.372, 95% CI: 0.174-0.695, P = 0.001) and low-density lipoprotein cholesterol (LDL-C) (OR = 0.295, 95% CI: 0.128-0.619, P<0.001) served as independent protective factors against MVD The combined model (Gensini score + Beclin 1 + LDL-C yielded an AUC of 0.936, with an optimal predictive probability cutoff of ≥0.664, a sensitivity of 0.911, and a specificity of 0.963. Compared to the basic model (Gensini score + LDL-C), the combined model exhibited a higher AUC, indicating that the addition of Beclin 1 effectively improved the predictive efficacy for MVD.
conclusionThe combination of Beclin 1 level, Gensini score, and LDL-C had good predictive value for MVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.